.Attribute Medicine, Posted online: 13 September 2024 doi:10.1038/ s41591-024-03261-7In the non-randomized period 3b/4 DESTINY-Breast12 research, trastuzumab deruxtecan (T-DXd) therapy of clients along with HER2+ advanced breast cancer cells and active or steady brain metastases revealed regular intracranial task as well as systemic efficiency of T-DXd.